HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andrea Griesinger Selected Research

Neoplasms (Cancer)

5/2020Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine.
1/2019Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo.
5/2014Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andrea Griesinger Research Topics

Disease

3Neoplasms (Cancer)
05/2020 - 05/2014
2Medulloblastoma
05/2020 - 05/2014
1Rhabdoid Tumor (Rhabdoid Tumors)
01/2019
1Preleukemia
07/2012
1Leukemia
11/2011

Drug/Important Bio-Agent (IBA)

2Proteins (Proteins, Gene)FDA Link
05/2014 - 11/2011
1adavosertibIBA
05/2020
1GemcitabineFDA Link
05/2020
1NucleotidesIBA
05/2020
1(+)-JQ1 compoundIBA
01/2019
1Phosphotransferases (Kinase)IBA
05/2014
1Thrombopoietin (c-mpl Ligand)IBA
07/2012
1GTP Phosphohydrolases (GTPases)IBA
11/2011

Therapy/Procedure

2Therapeutics
05/2014 - 11/2011
1Drug Therapy (Chemotherapy)
05/2014